Zealand Pharma Announces Publication of Petrelintide Phase 2 Trial Results in The Lancet Diabetes & Endocrinology

Zealand Pharma has announced the publication of results from its Phase 2 ZUPREME-1 trial for petrelintide in The Lancet Diabetes & Endocrinology. The investigational drug for chronic weight management demonstrated clinically meaningful, double-digit weight loss with a gastrointestinal tolerability profile comparable to placebo. The study also showed significant improvements in cardiometabolic disease risk factors. Additional data will be presented at the European Association for the Study of Diabetes (EASD) 2026 Congress.